Global Human Injection Flu Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Human Injection Flu Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Human Injection Flu Vaccine market size was valued at USD 7856 million in 2023 and is forecast to a readjusted size of USD 11110 million by 2030 with a CAGR of 5.1% during review period.

Influenza vaccines, also known as flu shots, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. Most provide modest to high protection against influenza; however, each year this varies. Evidence in adults over 65 years old is poor. They decrease the number of missed days of work by a half day on average. Vaccinating children may protect those around them.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Human Injection Flu Vaccine industry chain, the market status of 6 Months to 3 Years (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), > 3 Years (Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Human Injection Flu Vaccine.

Regionally, the report analyzes the Human Injection Flu Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Human Injection Flu Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Human Injection Flu Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Human Injection Flu Vaccine industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Human Injection Flu Vaccine market.

Regional Analysis: The report involves examining the Human Injection Flu Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Human Injection Flu Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Human Injection Flu Vaccine:

Company Analysis: Report covers individual Human Injection Flu Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Human Injection Flu Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (6 Months to 3 Years, > 3 Years).

Technology Analysis: Report covers specific technologies relevant to Human Injection Flu Vaccine. It assesses the current state, advancements, and potential future developments in Human Injection Flu Vaccine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Human Injection Flu Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Human Injection Flu Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

Market segment by Application
6 Months to 3 Years
> 3 Years

Major players covered
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
Jiangsu GDK
KM Biologics

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Human Injection Flu Vaccine product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Human Injection Flu Vaccine, with price, sales, revenue and global market share of Human Injection Flu Vaccine from 2019 to 2024.

Chapter 3, the Human Injection Flu Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Human Injection Flu Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Human Injection Flu Vaccine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Human Injection Flu Vaccine.

Chapter 14 and 15, to describe Human Injection Flu Vaccine sales channel, distributors, customers, research findings and conclusion.